Skip to main content
SpringerLink
Log in

Momentum builds around new antibiotic business models

  • News and Analysis
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

The Innovative Medicines Initiative's DRIVE-AB project joins the fray of task forces working to reinvigorate interest in antibiotics by developing reimbursement models that delink revenue from sales volume.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: The number of systemic antibiotic approvals declined steadily from 1980 to 2009.
Authors
  1. Asher Mullard
    View author publications

    You can also search for this author in PubMed Google Scholar

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mullard, A. Momentum builds around new antibiotic business models. Nat Rev Drug Discov 13, 711–713 (2014). https://doi.org/10.1038/nrd4455

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4455

  • Springer Nature Limited

This article is cited by

Search

Navigation